Wall Street brokerages expect that Incyte Co. (NASDAQ:INCY) will report $387.35 million in sales for the current quarter, Zacks Investment Research reports. Fourteen analysts have made estimates for Incyte’s earnings. The lowest sales estimate is $368.00 million and the highest is $434.50 million. Incyte reported sales of $384.08 million during the same quarter last year, which indicates a positive year over year growth rate of 0.9%. The business is expected to announce its next earnings report on Thursday, May 3rd.
On average, analysts expect that Incyte will report full year sales of $387.35 million for the current fiscal year, with estimates ranging from $1.61 billion to $1.88 billion. For the next financial year, analysts forecast that the business will report sales of $2.04 billion per share, with estimates ranging from $1.82 billion to $2.28 billion. Zacks’ sales averages are an average based on a survey of research analysts that follow Incyte.
Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.54. The company had revenue of $444.20 million for the quarter, compared to analysts’ expectations of $435.23 million. Incyte had a negative return on equity of 11.85% and a negative net margin of 20.38%. Incyte’s revenue for the quarter was up 36.0% compared to the same quarter last year. During the same period last year, the firm posted $0.05 EPS.
Shares of NASDAQ INCY opened at $69.83 on Friday. The stock has a market cap of $14,427.73, a P/E ratio of 109.11 and a beta of 0.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.99 and a current ratio of 4.01. Incyte has a 1-year low of $61.30 and a 1-year high of $142.45.
In other news, insider David W. Gryska sold 1,952 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $85.56, for a total value of $167,013.12. Following the completion of the transaction, the insider now owns 12,922 shares in the company, valued at approximately $1,105,606.32. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Reid M. Huber sold 1,958 shares of Incyte stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $85.55, for a total value of $167,506.90. The disclosure for this sale can be found here. Company insiders own 17.20% of the company’s stock.
A number of large investors have recently made changes to their positions in INCY. Financial Gravity Companies Inc. purchased a new position in Incyte during the fourth quarter valued at $120,000. Advantage Investment Management LLC raised its stake in Incyte by 1,233.3% during the fourth quarter. Advantage Investment Management LLC now owns 2,000 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 1,850 shares during the last quarter. Griffin Asset Management Inc. purchased a new position in Incyte during the fourth quarter valued at $200,000. Private Advisor Group LLC purchased a new position in Incyte during the third quarter valued at $203,000. Finally, Mission Wealth Management LP purchased a new position in Incyte during the fourth quarter valued at $213,000. Institutional investors and hedge funds own 93.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was published by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://dakotafinancialnews.com/2018/04/13/387-35-million-in-sales-expected-for-incyte-co-incy-this-quarter.html.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.